review Open AccessTop 1% cited

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Radiotherapy and Oncology · 2020 · Vol. 148 · pp. 157–166

Yolande Lievens✉(Ghent University Hospital)Matthias Gückenberger(University of Zurich)Daniel R. Gomez(The University of Texas MD Anderson Cancer Center)Morten Høyer(Aarhus University Hospital)Puneeth Iyengar(Southwestern Medical Center)I. Kindts(AZ Groeninge)Alejandra Romero(Erasmus MC)Daan Nevens(University of Antwerp)David A. Palma(London Health Sciences Centre)Catherine Park(UCSF Helen Diller Family Comprehensive Cancer Center)Umberto Ricardi(University of Turin)Marta Scorsetti(IRCCS Humanitas Research Hospital)James B. Yu(Yale University)Wendy A. Woodward(The University of Texas MD Anderson Cancer Center)

View via DOI Full-text PDF

Abstract

While significant heterogeneity exists in the current OMD definitions in the literature, consensus was reached on multiple key questions. Based on available data, OMD can to date be defined as 1-5 metastatic lesions, a controlled primary tumor being optional, but where all metastatic sites must be safely treatable. Consistent definitions and reporting are warranted and encouraged in ongoing trials and reports generating further evidence to optimize patient benefits.

Medical Imaging Techniques and Applications Management of metastatic bone disease Advanced Radiotherapy TechniquesRadiation oncologyMedical physicsPerspective (graphical)MedicineOncologyInternal medicineRadiation therapyComputer scienceArtificial intelligence